Jubilant Pharmova Ltd - 530019 - Receipt Of Rectification Order
Jubilant Pharmova's wholly-owned subsidiary, Jubilant Biosys, received a rectification order from the Assessing Officer in Noida disallowing Rs. 53.37 crore in brought forward tax losses for AY 2019-20. The company plans to appeal the order, expecting no material adverse financial implication.
Jun 30 2026 18:45:45
Jubilant Pharmova Ltd - 530019 - Rectification Order Received From Tax Department In The Matter Of Jubilant Generics Ltd
Jubilant Pharmova's wholly-owned subsidiary, Jubilant Generics Limited (JGL), received a rectification order from the Income Tax department. This order reduced tax adjustments from Rs.107.89 crore to Rs.42.41 crore, effectively restoring tax losses of Rs.65.48 crore for Assessment Year 2023-24.
Jun 24 2026 16:47:36
Jubilant Pharmova Ltd - 530019 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
Jubilant Pharmova's promoter group, comprising Hari Shanker Bhartia Family Trust and Shyam Sunder Bhartia Family Trust, created a pledge on 12.68% of the company's total equity shares on June 17, 2026. This action involves 38,969,300 equity shares.
Jun 19 2026 17:45:20
Jubilant Pharmova Ltd - 530019 - Completion Of USFDA Inspection
Jubilant Pharmova's subsidiary, Jubilant HollisterStier (JHS) CMO business, completed a USFDA inspection at its Spokane, WA facility. The inspection resulted in 8 observations, none of which were related to sterility assurance concerns, with JHS committed to responding within 15 business days.
Jun 19 2026 01:06:51
Read More